Is the GLP-1 party running down for Hims, and a study for the weekendIs the GLP-1 party running down for Hims, and a study for the weekend
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in your inbox. Good morning and happy Thursday! Yesterday it was announced that my colleague Usha Lee McFarling won the 2024 Victor Cohn Prize for Excellence in Medical Science Reporting. I’m genuinely so honored to work in the same newsroom as Read More
Surgeon Care Team Network Measures and Timely Breast Cancer TreatmentSurgeon Care Team Network Measures and Timely Breast Cancer Treatment
This cross-sectional study assesses associations of surgeon and care team patient-sharing networks with access to timely treatment among patients with breast cancer.
Persistent Neighborhood Poverty and Breast Cancer OutcomesPersistent Neighborhood Poverty and Breast Cancer Outcomes
This cohort study examines tumor characteristics, treatment, and mortality in women with breast cancer living in persistently impoverished census tracts.
miR-10b inhibition: A strategy for treating metastatic breast cancermiR-10b inhibition: A strategy for treating metastatic breast cancer
A new research paper was published in Oncotarget, titled “Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties.”
GLP-1 Agonists May Offer Protection Against Glaucoma in Type 2 DiabetesGLP-1 Agonists May Offer Protection Against Glaucoma in Type 2 Diabetes
(MedPage Today) — Diabetic patients treated with GLP-1 receptor agonists (GLP-1RAs) had a significantly lower risk of developing glaucoma as compared with metformin, a large retrospective cohort study showed. Patients treated with a GLP-1RA agonist… (MedPage Today) — Diabetic patients treated with GLP-1 receptor agonists (GLP-1RAs) had a significantly lower risk of developing glaucoma Read More
Considering taking Wegovy to lose weight? Here are the risks and benefits—and how it differs from OzempicConsidering taking Wegovy to lose weight? Here are the risks and benefits—and how it differs from Ozempic
The weight-loss drug Wegovy is now available in Australia. The weight-loss drug Wegovy is now available in Australia.
Scientists find way to starve breast cancer cellsScientists find way to starve breast cancer cells
Cancer cells have voracious appetites. And there are certain nutrients they can’t live without. Scientists have long hoped they might stop tumors in their tracks by cutting off an essential part of cancer cells’ diet. But these cells are crafty and often find a new way to get what they need. How? By reprogramming their metabolism and switching to backup food supplies.
T1D Stem Cell Success Story; Lilly’s Discount Tirzepatide Vials; Stelo Now AvailableT1D Stem Cell Success Story; Lilly’s Discount Tirzepatide Vials; Stelo Now Available
(MedPage Today) — A type 1 diabetes patient talked about her successful treatment with an investigational stem cell therapy currently in trials, noting that she hasn’t needed insulin since last August. (Washington Post) Eli Lilly said tirzepatide… (MedPage Today) — A type 1 diabetes patient talked about her successful treatment with an investigational stem Read More
Weight-loss drug Zepbound now in single-dose vials at half the priceWeight-loss drug Zepbound now in single-dose vials at half the price
Eli Lilly, maker of one of the blockbuster GLP-1 weight-loss drug Zepbound, says it will now offer the medication in single-dose vials at half the price currently available to consumers. Eli Lilly, maker of one of the blockbuster GLP-1 weight-loss drug Zepbound, says it will now offer the medication in single-dose vials at half the Read More
GLP-1 Agonists for Obesity—ReplyGLP-1 Agonists for Obesity—Reply
In Reply Dr Kurian and colleagues raise the option of surgical obesity treatments. These can be effective and cost-effective for individuals with appropriate indications. Yet many eligible patients opt for pharmacologic over surgical options. GLP-1 agonists also have far broader (and still expanding) indications, with at least 4-fold more US residents eligible. Identifying practical, effective, Read More